BridgeMD
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis
EU CTIS ID: 2023-508992-35-00
What this study is testing
To evaluate the efficacy of JNJ-81241459 compared with placebo in participants with moderate to severe plaque psoriasis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Be ≥18 (or the legal age of consent if it is higher in the jurisdiction in which the study is taking place) years of age at screening, inclusive.
- Diagnosis of plaque psoriasis
- Total BSA ≥10% at screening and baseline.
- Total PASI ≥12 at screening and baseline.
- Total IGA ≥3 at screening and baseline.
You likely can't join if
- Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular).
- Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium).
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
- A current diagnosis or history of IBD.
- Known allergies, hypersensitivity, or intolerance to JNJ-81241459 or its excipients (refer to the JNJ-81241459 IB).
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United Kingdom
- Japan
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United Kingdom; Japan; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.